Stimulate the bodys natural hormone production supporting growth, metabolism, and vitality
Probiotics can complement GLP-1 medications and support better appetite regulation and weight management when included as part of a balanced diet
Sources: FDA Drug Safety Communication, Jan 13, 2026 FDA prescribing labels: Ozempic, Wegovy, Mounjaro, Zepbound EMA / PRAC statement on NAION, June 6, 2025 UK MHRA Drug Safety Update on semaglutide & NAION Endocrine Society of India Clinical Practice Guidelines for Obesity, 2025 Disclaimer: This content is for educational purposes only and is not medical advice, diagnosis, or treatment
Maintaining consistent administration helps support these systemic processes without interruption
Side-by-Side Comparison Parameter Receptors Cagrilintide AMY1R/2R/3R + CTR Semaglutide GLP-1R Tirzepatide GLP-1R + GIPR Retatrutide GLP-1R + GIPR + Glucagon-R Parameter Half-life Cagrilintide ~7-8 days Semaglutide ~7 days Tirzepatide ~5 days Retatrutide ~6 days Parameter Dosing frequency Cagrilintide Once weekly Semaglutide Once weekly Tirzepatide Once weekly Retatrutide Once weekly Parameter Max studied dose Cagrilintide 4.5 mg/week (mono) Semaglutide 2.4 mg/week Tirzepatide 15 mg/week Retatrutide 12 mg/week Parameter Peak monotherapy weight loss Cagrilintide 11.8% at 68 wk Semaglutide 14.9-17% at 68 wk Tirzepatide 22.5% at 72 wk Retatrutide ~24% at 48 wk Parameter FDA status (June 2026) Cagrilintide Investigational Semaglutide Approved (2021) Tirzepatide Approved (2023) Retatrutide Investigational Parameter HbA1c reduction (T2D) Cagrilintide ~0.9 pp mono
